{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.23","upperLimit":"0.44","value":"0.33"},{"groupId":"OG001","lowerLimit":"0.054","upperLimit":"0.21","value":"0.12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"description":"Objective response rates (ORR) was investigator assessed. ORR is the rate of complete or partial responses, based on RECIST 1.1 criteria. A response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. The Fisher exact test will be used to compare the two treatment arms.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 60mg cabozantinib-s-malate PO QD for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (Cabozantinib-s-malate)"},{"description":"Patients receive 50mg sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm II (Sunitinib Malate)"}],"paramType":"NUMBER","populationDescription":"All enrolled patients.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Objective Response Rates","type":"SECONDARY","unitOfMeasure":"proportion of participants"}